Regeneron-JPM-20240108.pdf

1、J.P.Morgan Healthcare ConferenceJ A N U A R Y 8,2 0 2 4This non-promotional presentation contains investigational data as well as forward-looking statements;actual results may vary materially.2Strategy&Business UpdateJ.P.M o r g a n H e a l t h c a r e C o n f e r e n c e 2 0 2 4Co-Founder,Board Co-

2、Chair,President&Chief Executive Officer3Note regarding forward-looking statementsThis presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals,Inc.(Regeneron or theCompany),and actual event

3、s or results may differ materially from these forward-looking statements.Words such as anticipate,expect,intend,plan,believe,seek,estimate,variations of suchwords,and similar expressions are intended to identify such forward-looking statements,although not all forward-looking statements contain thes

4、e identifying words.These statements concern,and theserisks and uncertainties include,among others,the nature,timing,and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or itscollaborators or licensees(collectively,Regenerons Products)a

5、nd product candidates being developed by Regeneron and/or its collaborators or licensees(collectively,Regenerons Product Candidates)and research and clinical programs now underway or planned,including without limitation EYLEA(aflibercept)Injection,EYLEA HD(aflibercept)Injection 8 mg,Dupixent(dupilum

6、ab)Injection,Libtayo(cemiplimab)Injection,Praluent(alirocumab)Injection,Kevzara(sarilumab)Injection,Evkeeza(evinacumab)Injection,Veopoz(pozelimab)Injection,odronextamab,itepekimab,fianlimab,garetosmab,linvoseltamab,REGN5713-5714-5715,Regenerons other oncology programs(including its costimulatory bis